TELA Bio Launches OviTex Inguinal Reinforced Tissue Matrix in Europe for Hernia Repair

Tela Bio has launched OviTex Inguinal Reinforced Tissue Matrix, a reinforced tissue matrix for laparoscopic and robotic-assisted inguinal hernia repair in Europe. This is the only reinforced tissue matrix specifically engineered for this purpose, according to the company. Tela Bio is a medical technology company focused on providing innovative solutions for hernia repair.

TELA Bio (NASDAQ: TELA) has announced the European commercial launch of its OviTex Inguinal Reinforced Tissue Matrix, a product specifically designed for laparoscopic and robotic-assisted inguinal hernia repair. This launch follows the successful introduction of the product in the U.S. in 2024, where it generated over $1 million in first-year sales [1].

The OviTex Inguinal is a reinforced tissue matrix that utilizes ovine rumen with minimal polymer content, offering a clinically proven alternative to synthetic mesh for minimally invasive hernia repair. The product is available in two configurations—three- or four-layer anatomically shaped options—engineered for trocar compatibility in laparoscopic and robotic procedures.

The clinical efficacy of OviTex has been well-documented, with over 69,000 implantations and 40+ published works over the past eight years. A notable retrospective study of 259 patients showed a low recurrence rate of 1.2% at an average 1.5-year follow-up, demonstrating its effectiveness in robotic inguinal hernia repair [1].

The European launch of OviTex Inguinal represents a strategic market expansion for TELA Bio, targeting the growing trend of minimally invasive surgeries in Europe. The product will be showcased at the European Hernia Society Annual Congress in Paris, potentially accelerating early adoption among European hernia surgeons.

This expansion into the European market presents a significant opportunity for TELA Bio to capture market share in the growing minimally invasive hernia repair segment with a differentiated product.

References:
[1] https://www.stocktitan.net/news/TELA/tela-bio-announces-european-commercial-launch-of-ovi-tex-inguinal-aziyg4n9fhdm.html